US Capital Global Increased Financing for HealthTech Businesses during the COVID-19 Pandemic
San Francisco-based private financial group continues to experience rising demand for customized and scalable alternative financing solutions from HealthTech enterprises.
HealthTech is the fastest growing vertical within the healthcare sector. However, HealthTech can also come with larger overheads and require significantly higher levels of capital expenditure. Structuring and securing the right debt or equity business financing is therefore essential.
Providing Custom Financing for HealthTech Enterprises
US Capital Global’s HealthTech finance team understands this fast-growing vertical and the challenges HealthTech business owners and CFOs face. The group has deep experience in financing enterprises across a wide range of promising HealthTech areas, from disease tracking and disease testing to medical devices and equipment, biotechnology, biopharmaceutical research, and much more.
“US Capital Global has a reputation for being an innovator in the HealthTech financing space,” said Jeffrey Sweeney, Chairman and CEO at US Capital Global. “Over the past 24 months, the group has already facilitated or provided over $200 million in financing for middle market HealthTech enterprises. Our finance professionals understand the challenges and opportunities in the industry, and can design a financing solution that fits the specific needs of your business.”
Example Transactions
Disclaimer: Advisory services offered by US Capital Global refer exclusively to broker-lender advisory services for companies, and do not include any registered investment advisory.
To learn more about how your business can secure the funding it needs, email Jeffrey Sweeney, Chairman and CEO, at jsweeney@uscapglobal.com or call (415) 889-1010
